W. M. Van-baal, J. J. Emeis, M. J. Van-der-mooren, H. Kessel, P. Kenemans et al., Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study, Thromb Haemost, vol.83, pp.29-34, 2000.

M. S. Post, D. F. Hendriks, M. J. Van-der-mooren, W. M. Van-baal, J. R. Leurs et al., Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women, Journal of Internal Medicine, vol.84, issue.3, pp.245-251, 2002.
DOI : 10.1016/0378-5122(95)00950-7

L. A. Norris, J. Brosnan, J. Bonnar, J. Conard, C. Kluft et al., Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone, Thrombosis and Haemostasis, vol.100, pp.253-260, 2008.
DOI : 10.1160/TH07-12-0746

E. Hoibraaten, M. C. Mowinckel, H. De-ronde, R. M. Bertina, and P. M. Sandset, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial, British Journal of Haematology, vol.147, issue.2, pp.415-420, 2001.
DOI : 10.1016/S0140-6736(99)06092-4

V. Marque, M. Alhenc-gelas, G. Plu-bureau, E. Oger, and P. Y. Scarabin, The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women, Thromb Haemost, vol.86, pp.713-714, 2001.

L. M. Regan, D. J. Stearns-kurosawa, S. Kurosawa, J. Mollica, K. Fukudome et al., The Endothelial Cell Protein C Receptor: INHIBITION OF ACTIVATED PROTEIN C ANTICOAGULANT FUNCTION WITHOUT MODULATION OF REACTION WITH PROTEINASE INHIBITORS, Journal of Biological Chemistry, vol.271, issue.29, pp.17499-17503, 1996.
DOI : 10.1074/jbc.271.29.17499

G. Plu-bureau, M. G. Le, R. Sitruk-ware, J. C. Thalabard, and P. Mauvais-jarvis, Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease, British Journal of Cancer, vol.70, issue.2, pp.270-277, 1994.
DOI : 10.1038/bjc.1994.291

R. Sitruk-ware, New Progestogens, Drugs & Aging, vol.46, issue.1, pp.865-883, 2004.
DOI : 10.2165/00002512-200421130-00004

. Meyer, Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism, J Thromb Haemost, vol.4, issue.18, pp.71-7618, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00688975

V. Factor, 62) Mean values (SD) adjusted for age and body-mass index # Women received either nomegestrol acetate (n=19) or promegestone (n=14) Comparison to non-user group: * p<0, p.1